BioIQ, an Atlanta-based biotech company, has released an at-home saliva test that can detect Covid-19, Flu A / Flu B, and a 21 test respiratory panel from a single saliva sample.
The new development in testing, which is only available to health providers and employers, comes just two months after the company released its first Covid-19 saliva test.
“In the first phase of this battle against COVID-19, laboratories responded with testing but often this testing did not get to the people and businesses who needed it most. It lacked a delivery model and technology platform,” Justin Bellante, BioIQ CEO, said in a statement. “BioIQ is committed to helping the nation add testing capacity for the challenge, and not repeat shortcomings of the past, by adding innovative testing and tools such as telehealth, contact tracing and communication / notifications, in concert with a technology platform that enables delivery at scale and provides the access and convenience for consumers in a second-wave scenario.”
The new testing was made possible by a partnership between BioIQ and P23 Labs, a Little Rock, Ark.-based diagnostic center that created a solution to test one saliva sample for multiple illnesses for the upcoming flu season, according to a news release.
“Because consumers and employers are bracing for one of the most challenging flu seasons in history, P23 Labs thought it critical to have a solution supporting this unique circumstance, keeping the country and the economy moving forward,” Dr. Bernadette M. Mandes Wildemore, MD CMO of P23 Labs, said in a statement.